ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis

Biochem Biophys Res Commun. 2009 Feb 27;380(1):33-8. doi: 10.1016/j.bbrc.2009.01.013. Epub 2009 Jan 14.

Abstract

Modulation of angiogenesis is a promising approach for treating a wide variety of human diseases including ischemic heart disease and cancer. In this study, we show that ADAM-17 is an important regulator of several key steps during angiogenesis. Knocking down ADAM-17 expression using lentivirus-delivered siRNA in HUVECs inhibited cell proliferation and the ability of cells to form close contact in two-dimensional cultures. Similarly, ADAM-17 depletion inhibited the ability of HUVECs to form capillary-like networks on top of three-dimensional Matrigel as well as in co-culture with fibroblasts within a three-dimensional scaffold. In mechanistic studies, both baseline and VEGF-induced MMP-2 activation and Matrigel invasion were inhibited by ADAM-17 depletion. Based on our findings we propose that ADAM-17 is part of a novel pro-angiogenic pathway leading to MMP-2 activation and vessel formation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • ADAM Proteins / genetics
  • ADAM Proteins / physiology*
  • ADAM17 Protein
  • Cell Proliferation
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects
  • Endothelial Cells / physiology*
  • Gene Knockdown Techniques
  • Gene Silencing
  • Humans
  • Matrix Metalloproteinase 2 / metabolism
  • Neovascularization, Physiologic* / genetics
  • Umbilical Cord / cytology
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • Vascular Endothelial Growth Factor A
  • ADAM Proteins
  • Matrix Metalloproteinase 2
  • ADAM17 Protein
  • ADAM17 protein, human